Doximity Analysts Set $44.50 Average Price Target

Nine analysts cover the digital healthcare platform company, rating it a 'Moderate Buy'

Published on Mar. 4, 2026

Got story updates? Submit your updates here. ›

Shares of Doximity, Inc. (NYSE:DOCS) have received a 'Moderate Buy' consensus rating from nine analysts covering the firm, with an average 12-month price target of $44.50. The analysts' ratings range from 'hold' to 'strong buy' recommendations for the digital healthcare platform company headquartered in San Francisco.

Why it matters

Doximity operates a professional network and communications platform primarily for clinicians, providing tools to streamline clinical workflows, access medical information, and deliver telehealth services. Analyst price targets and ratings can influence investor sentiment and stock performance for the company.

The details

The nine analysts covering Doximity have issued a range of recommendations, with three giving a 'hold' rating, four a 'buy' rating, and two a 'strong buy' rating. The average 12-month price target set by the analysts is $44.50 per share. Recent analyst actions include Barclays upgrading Doximity to 'strong-buy' in December, Wells Fargo raising it to 'overweight' in January, and Royal Bank of Canada moving it to 'moderate buy' also in January. However, Wall Street Zen downgraded the stock to 'hold' in early January.

  • Doximity reported earnings on March 4, 2026.

The players

Doximity, Inc.

A digital healthcare platform company that provides communication and collaboration tools for clinicians, including secure messaging and telehealth capabilities.

Barclays

A multinational investment bank that upgraded Doximity to a 'strong-buy' rating in December.

Wells Fargo & Company

A major financial services company that raised its rating on Doximity to 'overweight' in January.

Royal Bank of Canada

A Canadian multinational financial services company that upgraded Doximity to a 'moderate buy' rating in January.

Wall Street Zen

A financial research firm that downgraded Doximity to a 'hold' rating in early January.

Got photos? Submit your photos here. ›

The takeaway

Analyst sentiment on Doximity appears mixed, with a range of ratings from 'hold' to 'strong buy' and an average price target of $44.50. The company's digital healthcare platform and telehealth capabilities continue to be the focus, as it navigates the evolving landscape of clinician communication and collaboration tools.